Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.4M | -$26.6M | -$32.5M | -$32.5M | -$29.9M | -$33.9M | -$51.5M | -$49.3M |
| Net income | -$20.5M | -$26.1M | -$32.8M | -$33.9M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| EPS (diluted) | -$58.44 | -$2.28 | -$1.81 | -$1.49 | -$0.45 | -$0.29 | -$0.47 | -$0.32 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.3M | -$23.1M | -$29.0M | -$28.9M | -$28.2M | -$31.7M | -$38.3M | -$42.1M |
| Capital expenditures | $158K | $9.00K | $32.0K | — | $159K | $137K | $35.0K | $12.0K |
| Free cash flow | -$18.4M | -$23.1M | -$29.0M | — | -$28.3M | -$31.8M | -$38.3M | -$42.1M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.20M | $57.3M | $45.0M | $36.8M | $12.6M | $32.4M | $34.1M | $18.9M |
| Total assets | $10.5M | $60.0M | $47.1M | $38.5M | $123M | $89.4M | $111M | $193M |
| Total liabilities | — | — | $19.8M | $21.4M | $15.6M | $6.86M | $11.3M | $10.2M |
| Shareholders' equity | -$109M | $54.5M | $27.3M | $17.1M | $107M | $82.5M | $99.6M | $183M |
| Retained earnings | -$109M | -$114M | -$147M | -$181M | -$210M | -$239M | -$287M | -$330M |
| Shares (wtd avg diluted) | 439K | 17.8M | 18.5M | 22.8M | 64.5M | 99.0M | 102M | 135M |
Every figure is extracted from Trevi Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.